CARLSBAD, CA – Palisade Bio, Inc. (NASDAQ:PALI), a biopharmaceutical firm, revealed the profitable completion of a examine indicating the potential of its drug candidate PALI-2108 for treating Ulcerative Colitis (UC). The examine targeted on the drug’s capability to inhibit TNF-α manufacturing, a pro-inflammatory cytokine, in an entire blood assay.
PALI-2108, an orally administered colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug, is being developed to focus on UC, an inflammatory bowel illness. In response to Palisade Bio’s Chief Medical Officer, Dr. Mitch Jones, the information from the examine helps the drug’s “strong anti-inflammatory potential.”
The examine included complete blood samples from 14 wholesome adults and measured the inhibitory focus (IC50) of TNF-α manufacturing. PALI-2108 demonstrated a imply IC50 of 0.022 µM, which was considerably decrease than that of the accredited PDE4 inhibitor, apremilast, which had an IC50 of 0.41 µM.
CEO JD (NASDAQ:) Finley expressed confidence within the operational execution resulting in the initiation of a Part 1 human scientific examine for PALI-2108 later this yr.
Palisade Bio’s focus stays on growing therapies for autoimmune, inflammatory, and fibrotic ailments. The corporate’s collaboration with Paraza Pharma, Inc., based mostly in Montreal, QC, has been instrumental in progressing their analysis initiatives.
The corporate’s forward-looking statements point out a dedication to advancing their analysis and enhancing affected person outcomes for these affected by UC and different inflammatory situations. Nonetheless, as with all biopharmaceutical improvement, these statements are topic to dangers and uncertainties that would have an effect on the precise outcomes and timing of occasions.
Buyers are reminded that this info relies on a press launch assertion from Palisade Bio. The corporate is making ready to maneuver ahead with scientific trials, aiming to handle the wants of UC sufferers with their novel therapeutic strategy.
take away adverts
.
InvestingPro Insights
As Palisade Bio, Inc. (NASDAQ:PALI) advances its drug candidate PALI-2108 for treating Ulcerative Colitis, buyers are intently monitoring the corporate’s monetary well being and market efficiency. In response to real-time information from InvestingPro, Palisade Bio has a market capitalization of 5.13M USD, reflecting the present valuation of the corporate available in the market. Regardless of the small dimension of the corporate, it is noteworthy that Palisade Bio holds extra cash than debt on its steadiness sheet, offering some monetary stability because it strikes in direction of scientific trials.
The corporate’s Value / Ebook ratio, as of the final twelve months ending in This fall 2023, stands at 0.45, suggesting that the inventory could also be undervalued in comparison with the corporate’s e book worth. This could possibly be of curiosity to worth buyers on the lookout for potential alternatives. Moreover, the corporate’s gross revenue margin has been reported at 100%, indicating that it was capable of convert all of its income into gross revenue over the identical interval, although this determine needs to be thought-about at the side of different monetary metrics, given the corporate’s working earnings margin of -5138.0%, signaling important working bills relative to income.
InvestingPro Ideas spotlight that analysts don’t anticipate the corporate will probably be worthwhile this yr and are rapidly burning via money, that are vital concerns for potential buyers. Furthermore, the worth of PALI shares has fallen considerably during the last yr, with a 1 Yr Value Whole Return of -75.78%, underscoring the high-risk nature of investing in biopharmaceutical firms of their early phases of drug improvement.
For these seeking to delve deeper into Palisade Bio’s financials and market efficiency, InvestingPro affords further ideas that would additional inform funding selections. With a complete of 11 ideas accessible, together with insights on gross sales progress and liquidity, buyers can discover these by visiting https://www.investing.com/professional/PALI. Bear in mind to make use of coupon code PRONEWS24 to get an extra 10% off a yearly or biyearly Professional and Professional+ subscription for extra in-depth evaluation and information.
take away adverts
.
This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.